Login / Signup

Delivery of Doxorubicin from Hyaluronic Acid-Modified Glutathione-Responsive Ferrocene Micelles for Combination Cancer Therapy.

Hong-Lin MaoFeng QianShun LiJia-Wei ShenCheng-Kun YeLei HuaLong-Zhen ZhangDong-Mei WuJun LuHengliang ShiHong-Mei Liu
Published in: Molecular pharmaceutics (2019)
A combination of different chemotherapy approaches can obtain the best response for many cancers. However, the greatest challenge is the development of a nanoparticle formulation that can encapsulate different chemotherapeutic agents to achieve the proper synergetic chemotherapy for the tumor. Here, amphiphilic ferrocenium-tetradecyl (Fe-C14) was constructed to form cationic micelles in an aqueous solution via self-assembly. Then, it was coated by hyaluronic acid (HA) through electrostatic interactions to generate HA-Fe-C14 micelles. The HA-Fe-C14 micelles were used to deliver doxorubicin (DOX), and it showed that the DOX could be released rapidly under a high-GSH tumor environment. The HA-Fe-C14/DOX micelles were able to accumulate efficiently in tumor and showed significant anticancer effect both in vitro and in vivo. These results suggest that HA-Fe-C14/DOX micelles are a useful drug delivery system that enhances synergic antitumor treatment effects.
Keyphrases
  • hyaluronic acid
  • cancer therapy
  • drug delivery
  • aqueous solution
  • drug release
  • metal organic framework
  • wastewater treatment
  • locally advanced
  • combination therapy
  • replacement therapy
  • fluorescent probe